Chemoimmunotherapy with bleomycin, vincristine, lomustine, dacarbazine (BOLD), and human leukocyte interferon for metastatic uveal melanoma
✍ Scribed by Seppo Pyrhönen; Marjo Hahka-Kemppinen; Timo Muhonen; Väinämö Nikkanen; Sebastian Eskelin; Paula Summanen; Ahti Tarkkanen; Tero Kivelä
- Publisher
- John Wiley and Sons
- Year
- 2002
- Tongue
- English
- Weight
- 103 KB
- Volume
- 95
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
✦ Synopsis
Background:
A phase ii trial comprising patients with metastatic uveal melanoma (stage ivb) was undertaken to determine the activity of bleomycin, vincristine, lomustine, and dacarbazine (bold) chemotherapy with human leukocyte interferon, as well as the progression-free and overall survival of the patients according to the substage before treatment.
Methods:
Twenty-two patients with histologically proven metastatic uveal melanoma received 15 mg of bleomycin (days 2 and 5), 1 mg/m(2) vincristine (days 1 and 4), 200 mg/m(2) dacarbazine (days 1 to 5), and 80 mg lomustine (day 1) every 4 weeks together with a leukocyte interferon preparation (3 x 10(6) iu daily for 6 weeks followed by 6 x 10(6) iu three times per week).
Results:
Of 20 evaluable patients, 3 (15%; 95% confidence interval [ci] 0-38) obtained a partial objective response in hepatic and extrahepatic sites and 11 (55%; 95% ci 32-77) showed stable disease after receiving more than two cycles. the median progression-free survival was 4 months (95% ci 2-10) and the median overall survival was 12 months (95% ci 8-22). eleven patients who had favorable pretreatment characteristics (stage ivba) survived a median of 17 months (95% ci 4-37) whereas 10 patients with less favorable characteristics (stage ivbb) survived a median of 11 months (95% ci 1-23). moderate toxicity occurred with this outpatient regimen.
Conclusions:
The bold/human leukocyte interferon regimen had modest activity against metastatic uveal melanoma in hepatic and extrahepatic sites. the median overall survival approached that reported for more aggressive intrahepatic therapy regimens. substage differences can significantly impact study outcomes. therefore, substage information should be reported to facilitate comparisons between studies.